Who Paid My Doc
Kiley Toder
Internal Medicine Johnston, RI Medical Doctor
NPI 1063640225 CMS profile 848955
1524 Atwood Ave, Suite 333, Johnston, RI 02919
General payments
$6,646
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Kiley Toder of Johnston, RI is reported in the CMS Open Payments database as having received $6,646 across 30 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $125 | 1 | |
| 2022 | General | $13 | 1 | |
| 2020 | General | $1,206 | 6 | |
| 2019 | General | $5,303 | 22 |
Beside peers
- Kiley Toder
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Kiley Toder were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Kiley Toder | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,303 | $159 | $48–$570 | $163 |
| 2020 | $1,206 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $13 | $141 | $42–$496 | $149 |
| 2023 | $125 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $0 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
2,447
Drug cost
$2,201,263
Branded share of claims
29.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Enbrel Sureclick Etanercept | Brand | 92 | $700,266 | |
| Xeljanz Tofacitinib Citrate | Brand | 79 | $457,929 | |
| Humira(Cf) Pen Adalimumab | Brand | 59 | $433,065 | |
| Enbrel Mini Etanercept | Brand | 23 | $189,264 | |
| Actemra Tocilizumab | Brand | 29 | $158,232 | |
| Enbrel Etanercept | Brand | 20 | $142,760 | |
| Tymlos Abaloparatide | Brand | 20 | $60,043 | |
| Methotrexate Methotrexate Sodium | Brand | 373 | $10,660 | |
| Allopurinol | Generic | 474 | $7,312 | |
| Hydroxychloroquine Sulfate | Generic | 159 | $6,853 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$1,522,476
Medicare patients
365
Services billed
154,655
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Osteoporosis | 46% | |
| Ischemic heart disease | 24% | |
| Diabetes | 23% | |
| Chronic kidney disease | 23% | |
| Depression | 23% | |
| COPD | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 19 | 12,100 | $409,332 |
| Injection, tocilizumab, 1 mg J3262 | Office | 11 | 60,984 | $287,265 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 18 | 18,550 | $169,304 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 | Office | 11 | 41,600 | $150,010 |
| Injection, denosumab, 1 mg J0897 | Office | 74 | 6,300 | $130,176 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg Q5104 | Office | 15 | 3,003 | $70,200 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 19 | 95 | $478 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
30 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Rhode Island
William Beliveau
Internal Medicine · Johnson, RI
Katarzyna Gilek-Seibert
Internal Medicine · Providence, RI
Randall Ingham
Internal Medicine · Providence, RI
Frank D'alessandro
Internal Medicine · Lincoln, RI
Gregory Allen
Internal Medicine · Cranston, RI
Richard Ruggieri
Internal Medicine · Providence, RI
Related records
Internal Medicine in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.